LAROTAXEL DIHYDRATE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C45H53NO14.2H2O
Molecular Weight	867.9312
Optical Activity	UNSPECIFIED
Defined Stereocenters	11 / 11
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]4[C@]5(C[C@H]5C[C@H]6OC[C@@]46OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C7=CC=CC=C7

InChI

InChIKey=SEFGUGYLLVNFIJ-QDRLFVHASA-N

InChI=1S/C45H53NO14.2H2O/c1-23-29(57-39(52)33(49)32(26-15-11-9-12-16-26)46-40(53)60-41(4,5)6)21-45(54)37(58-38(51)27-17-13-10-14-18-27)35-43(36(50)34(56-24(2)47)31(23)42(45,7)8)20-28(43)19-30-44(35,22-55-30)59-25(3)48;;/h9-18,28-30,32-35,37,49,54H,19-22H2,1-8H3,(H,46,53);2*1H2/t28-,29+,30-,32+,33-,34-,35+,37+,43-,44+,45-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	C45H53NO14
Molecular Weight	831.9006
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	11 / 11
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67531079 | https://www.cancer.gov/publications/dictionaries/cancer-drug/def/larotaxel | https://www.ncbi.nlm.nih.gov/pubmed/11472265

LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tubulin 69 Target ID: CHEMBL2095182 Sources: Weber, G.F. (2015) Molecular Therapies of Cancer, page 117, retrieved from: https://books.google.ru/books?id=dhs_CgAAQBAJ	Activator 1447

PubMed

Title	Date	PubMed
Larotaxel: broadening the road with new taxanes.	2009-08	19604119
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.	2008-07	18381372
Preclinical evaluation of new taxoids.	2001-09	11472265

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:06:21 GMT 2025` Edited by `admin` on `Mon Mar 31 18:06:21 GMT 2025`
Record UNII	23K148PYZO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RPR-109881A

Preferred Name

English

LAROTAXEL DIHYDRATE

Common Name

English

Code System Code Type Description

SMS_ID

300000052828